[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@SanofiUS](/creator/twitter/SanofiUS) "#NEWS: The @US_FDA accepted the filing of our sBLA for recently diagnosed stage X #Type1Diabetes for expedited review through the FDA Commissioners National Priority Voucher (CNPV) pilot program. Learn more" [X Link](https://x.com/SanofiUS/status/1980238131082436899) [@SanofiUS](/creator/x/SanofiUS) 2025-10-20T11:42Z 80.3K followers, XXX engagements "We have presented phase X data at #ESMO25 supporting the potential of our investigational therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Learn more CC: @OranoMed @RadioMedix" [X Link](https://x.com/SanofiUS/status/1980262983940067410) [@SanofiUS](/creator/x/SanofiUS) 2025-10-20T13:21Z 80.3K followers, XXX engagements "Results from a phase X study evaluating an investigational treatment for alpha-1 antitrypsin deficiency (#AATD) achieved all primary and key secondary endpoints. Read our press release to learn more about our research on this #RareDisease" [X Link](https://x.com/SanofiUS/status/1980984694406857144) [@SanofiUS](/creator/x/SanofiUS) 2025-10-22T13:08Z 80.3K followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@SanofiUS
"#NEWS: The @US_FDA accepted the filing of our sBLA for recently diagnosed stage X #Type1Diabetes for expedited review through the FDA Commissioners National Priority Voucher (CNPV) pilot program. Learn more"
X Link @SanofiUS 2025-10-20T11:42Z 80.3K followers, XXX engagements
"We have presented phase X data at #ESMO25 supporting the potential of our investigational therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Learn more CC: @OranoMed @RadioMedix"
X Link @SanofiUS 2025-10-20T13:21Z 80.3K followers, XXX engagements
"Results from a phase X study evaluating an investigational treatment for alpha-1 antitrypsin deficiency (#AATD) achieved all primary and key secondary endpoints. Read our press release to learn more about our research on this #RareDisease"
X Link @SanofiUS 2025-10-22T13:08Z 80.3K followers, XXX engagements
/creator/twitter::183033795/posts